COVID-19

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for…

1 year ago

AI in Life Sciences Market Poised for Explosive Growth with 27.9% CAGR Through 2029

AI Revolutionizes Life Sciences: Transforming Drug Discovery, Personalized Medicine, and Patient Outcome. BCC Research Study Projects a 27.9% CAGR, with…

1 year ago

2024 Collegiate Inventors Competition Finalists Showcase the Future of American Innovation

NORTH CANTON, Ohio, Sept. 26, 2024 /PRNewswire/ -- The Collegiate Inventors Competition®, an annual competition that has rewarded innovations, discoveries…

1 year ago

Plume Health Launches Interactive “Community Hub” for Trans Community to Mark Its Five Year Anniversary

Hub has already attracted more than 1,000 members – and is quickly expandingPlume has served more than 35,000 trans adults…

1 year ago

Nuvo Group Retains Intrepid Investment Bankers to Explore Investment and Strategic Alternatives

TEL AVIV, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Holdco Nuvo Group D.G Ltd (“Nuvo”), a pioneer in remote pregnancy…

1 year ago

Vanderbilt University School of Medicine Basic Sciences Adds Carterra’s LSAXT Instrument to Speed Drug and Vaccine Research and Advance Patient Care

The Center for Structural Biology in the School of Medicine Basic Sciences will be a hub of research innovation using Carterra's…

1 year ago

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

1 year ago

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

1 year ago

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many…

1 year ago

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose –…

1 year ago